In this article we discuss the challenges for manufacturers of therapeutics and diagnostics as they pursue the potential of companion diagnostics. Click below to read the article.
Navigating JCA for Orphan Medicinal Products: From scope simulation to pragmatic evidence generation for optimal patient access
The EU’s JCA framework is intended to streamline clinical evaluations and create a more consistent foundation for health technology assessments (HTAs) across...
